These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 2840035)

  • 1. [Cooperative study of postoperative long-term adjuvant therapy of breast cancer. First study of a series--comparative study between postoperative tegafur administration and no adjuvant chemotherapy].
    Terasawa T; Kousaki G; Sakai K; Senoo T; Taguchi T; Iwasa Z; Utsunomiya J; Okajima K; Okamoto E; Kawahara T
    Gan To Kagaku Ryoho; 1988 Jul; 15(7):2073-80. PubMed ID: 2840035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of subcutaneous mastectomy with radical mastectomy.
    Horiguchi J; Iino JHY ; Takei H; Koibuchi Y; Iijima K; Ikeda F; Ochiai R; Uchida K; Yoshida M; Yokoe T; Morishita Y
    Anticancer Res; 2001; 21(4B):2963-7. PubMed ID: 11712794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
    Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative loco-regional radiation therapy for breast cancer patients with four or more involved lymph nodes or extracapsular extension.
    Evron E; Barzily L; Rakowsky E; Ben-Baruch N; Sulkes J; Rizel S; Fenig E
    Isr Med Assoc J; 2005 Jul; 7(7):439-42. PubMed ID: 16011059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
    Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
    J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
    Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
    Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.
    Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1062-73. PubMed ID: 15234040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast.
    Botti C; Vici P; Lopez M; Scinto AF; Cognetti F; Cavaliere R
    J Am Coll Surg; 1995 Sep; 181(3):202-8. PubMed ID: 7670678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0).
    Deo SV; Bhutani M; Shukla NK; Raina V; Rath GK; Purkayasth J
    J Surg Oncol; 2003 Dec; 84(4):192-7. PubMed ID: 14756429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy of axillary node-negative carcinoma of the breast using doxorubicin and cyclophosphamide.
    Brooks RJ; Jones SE; Salmon SE; Chase EM; Davis SL; Moon TE; Giordano GF; Ketchel SJ; Jackson RA
    NCI Monogr; 1986; (1):135-7. PubMed ID: 3534586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adjuvant therapy for breast cancer patient with 10 or more involved nodes].
    Enomoto K
    Gan To Kagaku Ryoho; 1995 Apr; 22 Suppl 1():88-93. PubMed ID: 7747998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
    Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J
    Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis.
    Torrenga H; Fabry H; van der Sijp JR; van Diest PJ; Pijpers R; Meijer S
    J Surg Oncol; 2004 Oct; 88(1):4-7; discussion 7-8. PubMed ID: 15384064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Randomized comparative study of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) and UFT-tamoxifen regimens as adjuvant chemotherapy after surgery for breast cancer: Tochigi Prefectural Study Group for Post-Breast Cancer Adjuvant Chemotherapy].
    Tamura H; Kojima M; Kobayashi H; Ando J; Oka S; Fujisaki M; Wada N; Imoto S; Ikeda T
    Gan To Kagaku Ryoho; 2000 Jul; 27(7):993-1002. PubMed ID: 10925684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A long-term study of radiation therapy in t1-2 node-negative breast cancer patients in relation to the number of axillary nodes examined.
    Tai P; Yu E; Sadikov E; Joseph K
    Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):453-7. PubMed ID: 18947940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cooperative research on post-operative adjuvant therapy of breast cancer. Tohoku Society of Adjuvant Chemo-endocrine Therapy of Breast Cancer].
    Abe R; Tsuchiya A; Koie H; Ono K; Abo S; Saito K; Tsukamoto M; Sato T; Mori S; Motoki R
    Gan To Kagaku Ryoho; 1988 Sep; 15(9):2707-12. PubMed ID: 3137888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.